Immunoaffinity Chromatography Market Trends

Growth Drivers

• Financial and reliability benefits: There are several advantages of using biologics in the immunoaffinity chromatography market, including the healthcare quality and cost savings. In this regard AHRQ study published in 2022 states that IAC-purified biologics significantly reduced patient hospitalization rates by 20%, which is USD 3.7 billion in the U.S. healthcare expenditure in a span of two years. Besides, healthcare facilities are adopting IAC for improved purity, thereby mitigating lab errors by 25%. Hence, this higher efficiency is making immunoaffinity chromatography a priority in value-based care models.
   
• Enhanced integration of AI: The inclusion of smart technologies such as automation and AI-based functions in the immunoaffinity chromatography market is magnifying the acceptance. It is reported that 16% of new biolabs currently utilize AI-based immunoaffinity chromatography systems that appreciably reduce purification time by 42%. Besides, the leading firms such as Merck are deploying robotic resin packing that saves labor costs by 28%, attracting more firms to leverage AI in immunoaffinity chromatography.

Challenges

• High capital costs for IAC Automation: The immunoaffinity chromatography market faces a considerable hurdle in terms of extensive automation costs due to the adoption of AI. In this regard, as per a NIH report in 2024, the AI-based immunoaffinity chromatography systems cost above USD 2 million, making it challenging for emerging biotech firms to invest in this sector. On the other hand, to address this, Sartorious introduced leasing models that improved adoption rates by 25%.